Source comparison
Navigating the Nuances: A Comparison
To put BPC-157's status into context, it helps to compare it to other peptides researchers might be familiar with. Each has its own story and regulatory standing. Primary Research Area Tissue regeneration, gut health, anti-inflammation Wound healing, cell migr
This comparison does not assign a generated winner or score.
- To put BPC-157's status into context, it helps to compare it to other peptides researchers might be familiar with. Each has its own story and regulatory standing.
- Primary Research Area
- Tissue regeneration, gut health, anti-inflammation
- Wound healing, cell migration, cardiac repair
- Growth hormone release, anti-aging
- FDA Status
- Not approved. On 503A Category 2 list (no compounding).
- Not approved. Similar research-only status.
- FDA-approved drug (Geref) for specific medical uses.
- WADA Prohibited List
- Yes, S0 (Non-Approved Substances)
- Yes, S2 (Peptide Hormones, Growth Factors)
- Common Misconception
- It's a banned steroid. (It is neither.)
- It's the same as BPC-157. (It has a different mechanism.)
- It's available over the counter. (It requires a prescription.)
- Availability
- Research chemical suppliers
- Prescription from a licensed physician
- This table really highlights the complexity. You have a research chemical like BPC-157, a related one like TB 500 Thymosin Beta 4, and an FDA-approved drug like Sermorelin. All are peptides, but their legal pathways are worlds apart. It's why a one-size-fits-all answer to the question of legality simply doesn't work.